Mohammed Ahmed, DO
Nephrology · Bolingbrook, ILNPI 1962588061
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $858,173 of the $1,064,430 with a category attached, or 80.6%. 27 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 32.9% of the total. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,416 payments — averaging $751.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$350K
- Mallinckrodt Hospital Products Inc.$305K
- Aurinia Pharma U.S., Inc.$100K
- Mallinckrodt Enterprises LLC$81K
- Travere Therapeutics, Inc.$63K
- Bayer$53K
- plus $113K from 21 others
What the payments were for
- Consulting fees$50,7475%
- Speaking & faculty fees$858,17381%
- Travel & lodging$124,72212%
- Food & beverage$30,6393%
- Education$1000%
- Entertainment$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 477 | $349,831 |
| Mallinckrodt Hospital Products Inc. | 262 | $304,858 |
| Aurinia Pharma U.S., Inc. | 147 | $99,699 |
| Mallinckrodt Enterprises LLC | 85 | $80,524 |
| Travere Therapeutics, Inc. | 130 | $63,113 |
| Bayer | 68 | $53,171 |
| Ardelyx, Inc. | 52 | $41,191 |
| Boehringer Ingelheim | 26 | $25,132 |
| Calliditas Therapeutics US Inc. | 32 | $17,619 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 17 | $10,986 |
| Outset Medical Inc | 4 | $10,209 |
| GSK | 13 | $3,368 |
| Novartis | 16 | $1,552 |
| Amgen(2 entities) | 22 | $1,109 |
| AstraZeneca(2 entities) | 24 | $551 |
| Akebia Therapeutics Inc | 22 | $544 |
| Ceribell, Inc. | 2 | $188 |
| Genentech, Inc. | 1 | $150 |
| Medtronic | 1 | $147 |
| Baxter Healthcare | 1 | $107 |
| ANI Pharmaceuticals, Inc. | 3 | $79 |
| Novo Nordisk | 3 | $79 |
| Exthera Medical Corporation | 1 | $74 |
| Shire North American Group Inc | 4 | $67 |
| OPKO Pharmaceuticals, LLC | 1 | $35 |
| Vifor Pharma, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$380,430
- JYNARQUE$351,963
- LUPKYNIS$97,982
- Kerendia$52,212
- XPHOZAH 30 MG$40,227
- Filspari$24,905
- JARDIANCE$24,874
- TARPEYO$17,033
- SAMSCA$1,120
- Fabhalta$1,000
- KRYSTEXXA$772
- BENLYSTA$567
- IBSRELA$333
- (815) Thiola$216
- GAZYVA$150
- ELLIPSYS VASCULAR ACCESS SYSTEM$147
- ENTRESTO$119
- Renal - PD$107
How this compares
$1,064,430 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 16 | $90,862 |
| JardianceEmpagliflozin | 67 | $78,888 |
| Tolvaptan | 17 | $74,480 |
| KerendiaFinerenone | 47 | $64,819 |
| FarxigaDapagliflozin Propanediol | 28 | $33,158 |
| VelphoroSucroferric Oxyhydroxide | 12 | $29,851 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $29,822 |
| AuryxiaFerric Citrate | 12 | $14,480 |
| RayaldeeCalcifediol | 12 | $14,296 |
| Sevelamer Carbonate | 31 | $5,051 |
| Bumetanide | 34 | $1,283 |
| Irbesartan | 74 | $1,130 |
| Torsemide | 52 | $967 |
| Enoxaparin Sodium | 11 | $868 |
| Carvedilol | 51 | $788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $25,132 | $78,88867 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $10,986 | $74,48017 claims |
| BayerKerendia | $53,171 | $64,81947 claims |
| AstraZenecaFarxiga, Lokelma | $551 | $62,98051 claims |
| Akebia Therapeutics IncAuryxia | $544 | $14,48012 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $35 | $14,29612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.
Other nephrology in Bolingbrook
- Myles WolfChicago$2.1M
- Anis RaufHinsdale$453K
- Juan LermaEvergreen Park$351K
- Stuart SpragueEvanston$337K
- Suneel UdaniHinsdale$336K
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Omaima DeganiGurnee$184K
- Merry DownerSpringfield$156K
- Marco BonillaChicago$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.